Meridian Bioscience

Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.

Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.

In a marked contrast to its negative performance in February and March, the GenomeWeb Index rose more than 18 percent in April.

The company said the revenue increase is driven primarily by growth in the life science segment due to high demand for SARS-CoV-2 molecular products.

Diagnostics segment revenues for the company fell 5 percent to $38.4 million, and life sciences revenues dropped 15 percent to $12.6 million. 

The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.

The index's gain was well above the 13 percent increase of 2018, and almost reached the 39 percent increase it saw in 2017.

The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.